☆ 4.4 Article

Towards a future where Alzheimer's disease pathology is stopped before the onset of dementia

NATURE AGING (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Clinical Neurology

Global estimates on the number of persons across the Alzheimer's disease continuum

Anders Gustavsson et al.

Summary: This study synthesized literature on the prevalence of Alzheimer's disease (AD) at different stages and estimated the global number of individuals in the early stages of AD. The findings revealed that there are approximately 320 million individuals with AD dementia, 690 million with prodromal AD, and 315 million with preclinical AD globally. Together, these individuals constitute 22% of the population aged 50 and above. However, uncertainties remain in these estimates, particularly in low- and middle-income regions where biomarker studies are lacking.

ALZHEIMERS & DEMENTIA (2023)

添加到收藏夹

Article Clinical Neurology

Identifying best practices for disclosure of amyloid imaging results: A randomized controlled trial

Agnetha D. Fruijtier et al.

Summary: This study investigated the impact of six communication strategies on amyloid disclosure in mild cognitive impairment (MCI) patients. It found that risk communication best practices resulted in the highest information recall, while recall in emotional support was better than the basic and elaborate information strategies. Risk communication best practices also led to the highest uncertainty, while teach-back and emotional support contributed to the highest evaluations of the physician and information. Overall, risk communication best practices, attending to emotions, and teach-back techniques enhance information recall and contribute to positive care evaluations for amyloid-PET results.

ALZHEIMERS & DEMENTIA (2023)

添加到收藏夹

Article Psychology, Clinical

Neuropsychological assessment in the multicultural memory clinic: Development and feasibility of the TULIPA battery

Sanne Franzen et al.

Summary: This study aimed to develop a new neuropsychological test battery for culturally diverse populations and investigate its feasibility. The results showed that the completion rates of the test battery were generally high, but supplementary tests were administered less frequently. Complicating factors such as suboptimal effort, fatigue, and depression were frequently observed.

CLINICAL NEUROPSYCHOLOGIST (2023)

添加到收藏夹

Article Medicine, General & Internal

Lecanemab in Early Alzheimer's Disease

Christopher H. van Dyck et al.

Summary: Lecanemab, a humanized monoclonal antibody, reduced amyloid markers and showed improvement in cognition and function in early Alzheimer's disease patients. However, it also resulted in adverse events. Longer trials are needed to determine its efficacy and safety in early Alzheimer's disease.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Review Clinical Neurology

Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4

Michael W. Weiner et al.

Summary: ADNI4 aims to improve the validation of biomarkers for Alzheimer's disease clinical trials using new technologies and community-engaged approaches to recruit participants from underrepresented populations. The study will utilize an online portal for screening and conduct blood and digital cognitive testing. Additionally, MRI sequences and new PET tracers will be added to the project.

ALZHEIMERS & DEMENTIA (2023)

添加到收藏夹

Article Clinical Neurology

Smartphone-derived keystroke dynamics are sensitive to relevant changes in multiple sclerosis

Ka-Hoo Lam et al.

Summary: The study found that smartphone keystroke dynamics are sensitive to changes in disease activity, fatigue, and clinical disability in multiple sclerosis patients, detecting important changes beyond measurement error on a group level. Keystroke dynamics showed better responsiveness than commonly used clinical measures.

EUROPEAN JOURNAL OF NEUROLOGY (2022)

添加到收藏夹

Editorial Material Pharmacology & Pharmacy

Blood-Based Alzheimer's Biomarkers

[Anonymous]

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Review Clinical Neurology

Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review

Jetske van der Schaar et al.

Summary: The study provides an overview of considerations regarding the disclosure of AD pathology before the onset of dementia, categorizing them into clinical, personal, and societal contexts. The literature on this topic is diverse and contradictory, with a focus on harmful effects.

ALZHEIMERS RESEARCH & THERAPY (2022)

添加到收藏夹

Article Clinical Neurology

Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing

Fred B. Ketchum et al.

Summary: This article discusses the safety and psychological effects of AD biomarker testing, as well as the counseling and risk management before and after testing. It proposes a conceptual model to guide the different phases of testing.

ALZHEIMERS & DEMENTIA (2022)

添加到收藏夹

Article Genetics & Heredity

New insights into the genetic etiology of Alzheimer's disease and related dementias

Celine Bellenguez et al.

Summary: By characterizing the genetic landscape of Alzheimer's disease and related dementias, new loci have been identified and a new genetic risk score associated with the risk of future Alzheimer's disease and dementia has been generated.

NATURE GENETICS (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

Rik Ossenkoppele et al.

Summary: Abnormal amyloid and tau PET in cognitively unimpaired individuals is strongly associated with short-term cognitive decline and subsequent development of dementia.

NATURE MEDICINE (2022)

添加到收藏夹

Review Clinical Neurology

The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease

Oskar Hansson et al.

Summary: Blood-based markers have the potential to revolutionize the diagnosis and prognosis of Alzheimer's disease and improve the design of clinical trials. However, further research is needed before widespread use.

ALZHEIMERS & DEMENTIA (2022)

添加到收藏夹

Editorial Material Clinical Neurology

What Should the Goals Be for Diverse Recruitment in Alzheimer Clinical Trials?

Joshua D. Grill et al.

JAMA NEUROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment

Cherie Strikwerda-Brown et al.

Summary: The study confirmed the clinical value of NIA-AA biological research criteria in predicting whether older individuals with no cognitive impairment will develop AD symptoms in the near future, with most A+T+(N+) individuals developing AD symptoms within 2 to 3 years.

JAMA NEUROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers

Ris E. Jansen et al.

Summary: This study found that levels of A beta 42 and pTau in cerebrospinal fluid are more direct indicators of the pathogenesis of Alzheimer's disease than clinical diagnosis. Through a collaborative effort, novel associations with AD risk loci and multiple biological pathways related to A beta 42 and pTau were identified.

ACTA NEUROPATHOLOGICA (2022)

添加到收藏夹

Article Clinical Neurology

European consensus for the diagnosis of MCI and mild dementia: Preparatory phase

Cristina Festari et al.

Summary: This study developed a pan-European workflow for the etiological diagnosis of neurocognitive disorders in middle-old age based on biomarkers. The workflow was developed through a Delphi consensus method and a systematic literature review, aiming to provide guidance for the rational use of biomarkers in clinical practice.

ALZHEIMERS & DEMENTIA (2022)

添加到收藏夹

Editorial Material Clinical Neurology

The ATN Framework-Moving Preclinical Alzheimer Disease to Clinical Relevance

Wiesje M. van der Flier et al.

JAMA NEUROLOGY (2022)

添加到收藏夹

Article Clinical Neurology

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial

Michael J. Pontecorvo et al.

Summary: Significant reductions in plasma biomarkers pTau(217) and glial fibrillary acidic protein were observed following donanemab treatment in patients with early symptomatic Alzheimer disease. These easily accessible plasma biomarkers might provide additional evidence of Alzheimer disease pathology change through anti-amyloid therapy. Usefulness in assessing treatment response will require further evaluation.

JAMA NEUROLOGY (2022)

添加到收藏夹

Review Clinical Neurology

Blood-based biomarkers for Alzheimer's disease: towards clinical implementation

Charlotte E. Teunissen et al.

Summary: Recent research suggests that blood-based biomarkers for Alzheimer's disease may become a reality, with consistent results across different cohorts. Additionally, other blood-based biomarkers can provide information about disease progression and treatment effects.

LANCET NEUROLOGY (2022)

添加到收藏夹

Article Geriatrics & Gerontology

Putting primary prevention of dementia on everybody's agenda

Jan Steyaert et al.

Summary: Dementia poses a significant challenge to society, with the number of cases expected to rise rapidly as life expectancy increases. Recent research highlights primary prevention as a promising strategy in addressing the challenges of dementia.

AGING & MENTAL HEALTH (2021)

添加到收藏夹

Review Cell Biology

Diagnostic performance of digital cognitive tests for the identification of MCI and dementia: A systematic review

Joyce Y. C. Chan et al.

Summary: Digital cognitive tests showed good diagnostic performances for MCI and dementia in older adults, with most tests having comparable performances to traditional paper-and-pencil tests and some tests demonstrating high sensitivity and specificity. However, there are limited validation studies for digital tests, indicating a need for further research on these new forms of cognitive data for the early detection of MCI and dementia.

AGEING RESEARCH REVIEWS (2021)

添加到收藏夹

Article Neurosciences

An Exploratory Study of the Development and Pilot Testing of an Interactive Visual Tool of Neuropsychological Test Results in Memory Clinics

Angelique A. A. Gruters et al.

Summary: A web-based visual tool was developed to improve understanding and information retention of neuropsychological results, as well as psychologist-patient communication. The tool was optimized through an iterative approach and pilot study, with psychologists rating its usability highly. Feedback from patients, family members, and psychologists indicated the value of the visual display in clinical practice.

JOURNAL OF ALZHEIMERS DISEASE (2021)

添加到收藏夹

Review Radiology, Nuclear Medicine & Medical Imaging

The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers

N. J. Ashton et al.

Summary: The development of blood biomarkers for Alzheimer's disease has shown promise for dementia diagnosis and early detection. Plasma p-tau has demonstrated analytical and clinical validity, while A beta's maturity level remains partially achieved. Despite progress in phases 1 through 3, more data is needed on covariate effects on biomarker measurement.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Review Radiology, Nuclear Medicine & Medical Imaging

2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework

A. Leuzy et al.

Summary: By utilizing the Biomarker Roadmap methodology, experts assessed the maturity levels of CSF AD biomarkers in 2019 and found significant advancements in a unified protocol for CSF handling, introduction of certified reference methods for A beta 42, and fully automated assays. While progress has been made in phases one through three, further work is needed in phases four and five to assess real world performance and impact/cost.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2021)

添加到收藏夹

Article Clinical Neurology

The Alzheimer's disease drug development landscape

Pieter van Bokhoven et al.

Summary: In the last 15 years, the diagnosis of Alzheimer's disease (AD) has shifted from syndromal to a biomarker construct based on pathological hallmarks. Genetic risk factors for AD have been identified, providing insight into the molecular basis of the disease. The AD drug development pipeline is diversifying in terms of targets and treatment modalities, with amyloid-targeting therapies remaining a prominent avenue of development.

ALZHEIMERS RESEARCH & THERAPY (2021)

添加到收藏夹

Review Clinical Neurology

Dementia risk communication. A user manual for Brain Health Services-part 3 of 6

Leonie N. C. Visser et al.

Summary: As evidence suggests dementia incidence can be reduced through prevention programs targeting risk factors, a new generation of brain health services is envisioned to accelerate the implementation of such programs. Specifically, risk communication plays a crucial role in enabling individuals at risk to make informed decisions and take action to protect themselves. However, communication about dementia risk is complex and challenging, highlighting the need for further research to develop effective communication strategies.

ALZHEIMERS RESEARCH & THERAPY (2021)

添加到收藏夹

Review Clinical Neurology

Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services-part 1 of 6

Daniele Altomare et al.

Summary: Dementia prevention is a public health priority with significant benefits for individuals and society; incidence of dementia is decreasing in higher-income countries, suggesting the feasibility of prevention; current memory clinics are ill-equipped to address the demands of cognitively unimpaired individuals concerned about their risk of dementia.

ALZHEIMERS RESEARCH & THERAPY (2021)

添加到收藏夹

Article Health Care Sciences & Services

Assessing the Views of Professionals, Patients, and Care Partners Concerning the Use of Computer Tools in Memory Clinics: International Survey Study

Aniek M. van Gils et al.

Summary: The study found that most clinicians are willing to use computer tools in memory clinics, with user-friendliness and increased diagnostic accuracy being the main factors driving adoption. However, barriers such as inadequate integration with electronic patient records and fear of losing clinical information need to be overcome. Patients and care partners also have a positive attitude towards clinicians using computer tools, and even see the possibility of using the tools themselves as helpful.

JMIR FORMATIVE RESEARCH (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Clinicians' communication with patients receiving a MCI diagnosis: The ABIDE project

Leonie N. C. Visser et al.

PLOS ONE (2020)

添加到收藏夹

Article Clinical Neurology

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling data from four cohorts

Thomas K. Karikari et al.

LANCET NEUROLOGY (2020)

添加到收藏夹

Article Clinical Neurology

World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia

Miia Kivipelto et al.

ALZHEIMERS & DEMENTIA (2020)

添加到收藏夹

Review Medicine, General & Internal

Dementia prevention, intervention, and care: 2020 report of the Lancet Commission

Gill Livingston et al.

LANCET (2020)

添加到收藏夹

Article Clinical Neurology

Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics

Betty M. Tijms et al.

BRAIN (2020)

添加到收藏夹

Letter Neurosciences

Mechanisms underlying resilience in ageing

Yaakov Stern et al.

NATURE REVIEWS NEUROSCIENCE (2019)

添加到收藏夹

Article Clinical Neurology

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

Sven J. van der Lee et al.

ACTA NEUROPATHOLOGICA (2019)

添加到收藏夹

Review Clinical Neurology

A brief history of Alzheimer disease Multiple meanings separated by a common name

David S. Knopman et al.

NEUROLOGY (2019)

添加到收藏夹

Article Clinical Neurology

Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework

Clifford R. Jack et al.

JAMA NEUROLOGY (2019)

添加到收藏夹

Review Health Care Sciences & Services

Current State of Digital Biomarker Technologies for Real-Life, Home-Based Monitoring of Cognitive Function for Mild Cognitive Impairment to Mild Alzheimer Disease and Implications for Clinical Care: Systematic Review

Antoine Piau et al.

JOURNAL OF MEDICAL INTERNET RESEARCH (2019)

添加到收藏夹

Article Clinical Neurology

ABIDE Delphi study: topics to discuss in diagnostic consultations in memory clinics

Agnetha D. Fruijtier et al.

ALZHEIMERS RESEARCH & THERAPY (2019)

添加到收藏夹

Article Clinical Neurology

Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study

Ingrid S. van Maurik et al.

LANCET NEUROLOGY (2019)

添加到收藏夹

Article Clinical Neurology

The Brain Health Registry: An internet-based platform for recruitment, assessment, and longitudinal monitoring of participants for neuroscience studies

Michael W. Weiner et al.

ALZHEIMERS & DEMENTIA (2018)

添加到收藏夹

Review Clinical Neurology

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

Clifford R. Jack et al.

ALZHEIMERS & DEMENTIA (2018)

添加到收藏夹

Article Clinical Neurology

The effect of &ITAPOE&IT and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study

Sven J. van der Lee et al.

LANCET NEUROLOGY (2018)

添加到收藏夹

Article Clinical Neurology

Effect of the Apolipoprotein E Genotype on Cognitive Change During a Multidomain Lifestyle Intervention A Subgroup Analysis of a Randomized Clinical Trial

Alina Solomon et al.

JAMA NEUROLOGY (2018)

添加到收藏夹

Article Clinical Neurology

Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease

Stephan Mueller et al.

ALZHEIMERS & DEMENTIA (2018)

添加到收藏夹

Review Neurosciences

Secular Trends in Dementia Prevalence and Incidence Worldwide: A Systematic Review

Blossom C. M. Stephan et al.

JOURNAL OF ALZHEIMERS DISEASE (2018)

添加到收藏夹

Article Biochemistry & Molecular Biology

Characterization of pathogenic SORL1 genetic variants for association with Alzheimer's disease: a clinical interpretation strategy

Henne Holstege et al.

EUROPEAN JOURNAL OF HUMAN GENETICS (2017)

添加到收藏夹

Review Clinical Neurology

The changing prevalence and incidence of dementia over time - current evidence

Yu-Tzu Wu et al.

NATURE REVIEWS NEUROLOGY (2017)

添加到收藏夹

Article Ethics

Amnestic MCI Patients' Perspectives toward Disclosure of Amyloid PET Results in a Research Context

Gwendolien Vanderschaeghe et al.

NEUROETHICS (2017)

添加到收藏夹

Review Clinical Neurology

Communicating mild cognitive impairment diagnoses with and without amyloid imaging

Joshua D. Grill et al.

ALZHEIMERS RESEARCH & THERAPY (2017)

添加到收藏夹

Article Emergency Medicine

What Is Shared Decision Making? (and What It Is Not)

Marleen Kunneman et al.

ACADEMIC EMERGENCY MEDICINE (2016)

添加到收藏夹

Editorial Material Clinical Neurology

The crisis in recruitment for clinical trials in Alzheimer's and dementia: An action plan for solutions

Keith N. Fargo et al.

ALZHEIMERS & DEMENTIA (2016)

添加到收藏夹

Review Neurosciences

Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment

Jennifer H. Lingler et al.

JOURNAL OF ALZHEIMERS DISEASE (2016)

添加到收藏夹

Article Medicine, General & Internal

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia A Meta-analysis

Willemijn J. Jansen et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)

添加到收藏夹

Article Medicine, General & Internal

A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial

Tiia Ngandu et al.

LANCET (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Comparing the Health State Preferences of Older Persons, Informal Caregivers and Healthcare Professionals: A Vignette Study

Cynthia S. Hofman et al.

PLOS ONE (2015)

添加到收藏夹

Article Clinical Neurology

Midlife risk score for the prediction of dementia four decades later

Lieza G. Exalto et al.

ALZHEIMERS & DEMENTIA (2014)

添加到收藏夹

Article Clinical Neurology

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease

Frank Jessen et al.

ALZHEIMERS & DEMENTIA (2014)

添加到收藏夹

Article Medicine, General & Internal

Variant of TREM2 Associated with the Risk of Alzheimer's Disease

Thorlakur Jonsson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Article Medicine, General & Internal

TREM2 Variants in Alzheimer's Disease

Rita Guerreiro et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Article Multidisciplinary Sciences

A mutation in APP protects against Alzheimer's disease and age-related cognitive decline

Thorlakur Jonsson et al.

NATURE (2012)

添加到收藏夹

Article Medicine, General & Internal

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

Randall J. Bateman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

添加到收藏夹

Review Psychology, Clinical

Subjective needs of people with dementia: a review of the literature

Henriette G. van der Roest et al.

INTERNATIONAL PSYCHOGERIATRICS (2007)

添加到收藏夹

Article Clinical Neurology

Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study

Miia Kivipelto et al.

LANCET NEUROLOGY (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.